Top

16-04-2024 | NSCLC | RESEARCH ARTICLE

Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment

Authors: Ke Wang, Manyi Xu, Yanhua Wang, Chunwei Xu, Yue Hao, Zhengbo Song

Published in: Clinical and Translational Oncology

Abstract

Purpose

The treatment of the advanced non-small cell lung cancer (NSCLC) with KRAS mutation has been closely paid more attention. The aim of this study is to investigate the efficacy of different first-line regimens in advanced KRAS-mutated non-small cell lung cancer.

Methods

In our retrospective study, we collected patients with advanced NSCLC with KRAS mutation in Zhejiang Cancer Hospital between January 2015 and May 2023. We analyzed the benefit of different first-line therapy according to theraputic methods and the differential effect of the same treatment method among KRAS-mutated subtypes. We divided the patients into group A (A1, chemotherapy alone; A2, immunotherapy alone) and group B (B1, chemotherapy plus immunotherapy; B2, chemotherapy combined with antiangiogenic therapy; B3, chemotherapy combined with immunotherapy plus antiangiogenic therapy). The Kaplan–Meier survival curve was used to reflect the PFS and OS of different methods. The objective response rate (ORR) and the disease control rate (DCR) were used to evaluated the response.

Results

We enrolled 227 patients including eighty-two with KRAS G12C mutation. The ORR and DCR of first-line treatment in the overall population were 32.2% and 80.6% respectively. The median PFS was 6.7 months and the median OS was 17.4 months for the overall population. The PFS of the Group B was significantly better than that of the Group A (7.7 months vs 5.4 months, P = 0.003), while no significant difference in OS was observed (19.4 months vs 15.0 months, P = 0.077). In the Group B, chemotherapy combined immunotherapy with antiangiogenic therapy showed better PFS than chemotherapy plus immunotherapy (14.1 months vs 7.7 months, P = 0.049), and OS also showed that tendency of difference (31.9 months vs 19.3 months, P = 0.158). There was no statistically significant difference between KRAS G12C and non-G12C mutation according to first-line treatment methods, whereas patients with TP53 co-mutation showed a better survival benefit (OS, 23.7 vs 12.5 months, P = 0.023).

Conclusion

In the first-line treatment, combination regimen has advantages over single regimen. Among them, chemotherapy combined with immunotherapy plus antiangiogenic therapy can achieve significant efficacy benefits.

Available only for authorised users

Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624–39. https://doi.org/10.1038/s41571-023-00798-3.CrossRefPubMed

Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016;10(2):113–29. https://doi.org/10.1177/1753465815617871.CrossRefPubMed

Adderley H, Blackhall FH, Lindsay CR. KRAS-mutant non-small cell lung cancer: converging small molecules and immune checkpoint inhibition. EBioMedicine. 2019;41:711–6. https://doi.org/10.1016/j.ebiom.2019.02.049.CrossRefPubMedPubMedCentral

Prior IA, Hood FE, Hartley JL. The frequency of ras mutations in cancer. Cancer Res. 2020;80(14):2969–74. https://doi.org/10.1158/0008-5472.CAN-19-3682.CrossRefPubMedPubMedCentral

Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p G12C mutation. N Engl J Med. 2021;384(25):2371–81. https://doi.org/10.1056/NEJMoa2103695.CrossRefPubMedPubMedCentral

Ou SI, Jänne PA, Leal TA, Rybkin II, Sabari JK, Barve MA, et al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1). J Clin Oncol. 2022;40(23):2530–8. https://doi.org/10.1200/JCO.21.02752.CrossRefPubMedPubMedCentral

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497–530. https://doi.org/10.6004/jnccn.2022.0025.CrossRefPubMed

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358–76. https://doi.org/10.1016/j.annonc.2022.12.013.CrossRefPubMed

Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40. https://doi.org/10.1186/s12943-023-01740-y.CrossRefPubMedPubMedCentral

10.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774.CrossRefPubMed

11.

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7.CrossRefPubMed

12.

Uehara Y, Watanabe K, Hakozaki T, Yomota M, Hosomi Y. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations. Thorac Cancer. 2022;13(11):1703–11. https://doi.org/10.1111/1759-7714.14448.CrossRefPubMedPubMedCentral

13.

Qi W, Xi D, Bai Y, Liu L, Ma Y, Yin Z, et al. Case report: chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. Front Pharmacol. 2023;12(14):1026135. https://doi.org/10.3389/fphar.2023.1026135.CrossRef

14.

Cinausero M, Laprovitera N, De Maglio G, Gerratana L, Riefolo M, Macerelli M, et al. KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Ther Adv Med Oncol. 2019;14(11):1758835919885540. https://doi.org/10.1177/1758835919885540.CrossRef

15.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–46. https://doi.org/10.1200/JCO.18.00149.CrossRefPubMed

16.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30. https://doi.org/10.1016/S0140-6736(18)32409-7.CrossRefPubMed

17.

Mok TSK, Lopes G, Cho BC, Kowalski DM, Kasahara K, Wu YL, et al. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann Oncol. 2023;34(4):377–88. https://doi.org/10.1016/j.annonc.2023.01.011.CrossRefPubMed

18.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. https://doi.org/10.1056/NEJMoa1507643.CrossRefPubMedPubMedCentral

19.

Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro CJ, et al. Five-year outcomes from the randomized, phase iii trials checkMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–33. https://doi.org/10.1200/JCO.20.01605.CrossRefPubMedPubMedCentral

20.

Bironzo P, Cani M, Jacobs F, Napoli VM, Listì A, Passiglia F, et al. Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy. Cancer. 2023;129(11):1662–71. https://doi.org/10.1002/cncr.34731.CrossRefPubMed

21.

Gu X, Si J, Guan Y, Xu Y, Shao L, Zhang Y, et al. Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: a retrospective analysis. Open Med (Wars). 2023;18(1):20230653. https://doi.org/10.1515/med-2023-0653.CrossRefPubMed

22.

Zhao Y, Guo S, Deng J, Shen J, Du F, Wu X, et al. VEGF/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment. Int J Biol Sci. 2022;18(9):3845–58. https://doi.org/10.7150/ijbs.70958.CrossRefPubMedPubMedCentral

23.

Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64(11):3731–6. https://doi.org/10.1158/0008-5472.CAN-04-0074.CrossRefPubMed

24.

Wu JB, Tang YL, Liang XH. Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy. Onco Targets Ther. 2018;17(11):6901–9. https://doi.org/10.2147/OTT.S172042.CrossRef

25.

Chen H, Huang D, Lin G, Yang X, Zhuo M, Chi Y, et al. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-mutant non-small cell lung cancer. Cancer Med. 2022;11(19):3581–92. https://doi.org/10.1002/cam4.4739.CrossRefPubMedPubMedCentral

26.

Ghimessy AK, Gellert A, Schlegl E, Hegedus B, Raso E, Barbai T, et al. KRAS mutations predict response and outcome in advanced lung adenocarcinoma patients receiving first-line bevacizumab and platinum-based chemotherapy. Cancers (Basel). 2019;11(10):1514. https://doi.org/10.3390/cancers11101514.CrossRefPubMed

27.

West HJ, McCleland M, Cappuzzo F, Reck M, Mok TS, Jotte RM, et al. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. J Immunother Cancer. 2022;10(2):e003027. https://doi.org/10.1136/jitc-2021-003027.CrossRefPubMedPubMedCentral

28.

Wang MM, Zhang Y, Wu S, Zhang SY, Shan HL, Yang XM, et al. Clinical outcomes of KRAS-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: a retrospective observational study. Transl Lung Cancer Res. 2023;12:2030–9. https://doi.org/10.21037/tlcr-23-449.CrossRefPubMedPubMedCentral

29.

Liu Y, Gao Y, Wang Y, Zhao C, Zhang Z, Li B, et al. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. BMC Cancer. 2022;22(1):1175. https://doi.org/10.1186/s12885-022-10236-9.CrossRefPubMedPubMedCentral

30.

Bischoff P, Reck M, Overbeck T, Christopoulos P, Rittmeyer A, Lüders H, et al. Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for nonsquamous programmed death-ligand 1-high (≥50%) NSCLC in the German national network genomic medicine lung cancer. J Thorac Oncol. 2023;S1556–0864(23):02423–31. https://doi.org/10.1016/j.jtho.2023.12.015.CrossRef

Title: Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment
Authors: Ke Wang
Manyi Xu
Yanhua Wang
Chunwei Xu
Yue Hao
Zhengbo Song
Publication date: 16-04-2024
Publisher: Springer International Publishing
Keywords: NSCLC
NSCLC
Cytostatic Therapy
Published in: Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-024-03485-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine